ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 14,292 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 14,292 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $29.22, for a total value of $417,612.24. Following the sale, the executive vice president owned 67,828 shares of the company’s stock, valued at $1,981,934.16. The trade was a 17.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ACADIA Pharmaceuticals Price Performance

NASDAQ ACAD traded up $0.76 during mid-day trading on Friday, hitting $29.21. The company’s stock had a trading volume of 1,782,652 shares, compared to its average volume of 1,684,264. ACADIA Pharmaceuticals Inc. has a 52-week low of $19.69 and a 52-week high of $29.48. The stock’s fifty day simple moving average is $24.24 and its two-hundred day simple moving average is $23.23. The firm has a market capitalization of $5.00 billion, a P/E ratio of 13.16, a price-to-earnings-growth ratio of 19.47 and a beta of 0.81.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The firm had revenue of $308.00 million for the quarter, compared to analysts’ expectations of $296.55 million. During the same period in the previous year, the company posted $0.16 earnings per share. ACADIA Pharmaceuticals’s revenue was up 16.4% compared to the same quarter last year. On average, equities analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ACAD. BlackRock Inc. acquired a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at about $569,634,000. Pallas Capital Advisors LLC acquired a new position in shares of ACADIA Pharmaceuticals in the second quarter worth about $293,000. Deutsche Bank AG purchased a new position in ACADIA Pharmaceuticals in the second quarter valued at about $6,521,000. Rice Hall James & Associates LLC acquired a new stake in ACADIA Pharmaceuticals during the 2nd quarter valued at approximately $15,658,000. Finally, Uniting Wealth Partners LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at approximately $278,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on ACAD shares. Royal Bank Of Canada increased their price target on ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the company an “outperform” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday. BMO Capital Markets raised their target price on ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, July 21st. Weiss Ratings reissued a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Finally, Stifel Nicolaus increased their price objective on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 21st. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $33.44.

ACADIA Pharmaceuticals News Roundup

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.